Should You Buy Biora Therapeutics Inc (BIOR) Stock on Wednesday?

The market has been neutral on Biora Therapeutics Inc (BIOR) stock recently. BIOR gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Biora Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on BIOR!

See Full BIOR Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With BIOR Stock Today?

Biora Therapeutics Inc (BIOR) stock is trading at $1.09 as of 12:08 PM on Wednesday, Aug 10, a gain of $0.32, or 40.91% from the previous closing price of $0.77. The stock has traded between $0.84 and $1.15 so far today. Volume today is high. So far 22,970,506 shares have traded compared to average volume of 1,473,216 shares.

More About Biora Therapeutics Inc

Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States. Click Here to get the full Stock Report for Biora Therapeutics Inc stock.